Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.
Identifieur interne : 000056 ( PubMed/Checkpoint ); précédent : 000055; suivant : 000057Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.
Auteurs : Michael S. Kiernan [États-Unis] ; Douglas Gregory [États-Unis] ; Mark J. Sarnak [États-Unis] ; Patrick Rossignol [France] ; Joseph Massaro [États-Unis] ; Robb Kociol [États-Unis] ; Faiez Zannad [France] ; Marvin A. Konstam [États-Unis]Source :
- JACC. Heart failure [ 2213-1787 ] ; 2015.
Descripteurs français
- KwdFr :
- Antagonistes des récepteurs aux angiotensines (administration et posologie), Défaillance cardiaque (physiopathologie), Défaillance cardiaque (traitement médicamenteux), Facteurs temps, Humains, Losartan (administration et posologie), Rein (), Rein (physiopathologie), Relation dose-effet des médicaments, Résultat thérapeutique, Taux de filtration glomérulaire (), Études de suivi, Études rétrospectives.
- MESH :
- administration et posologie : Antagonistes des récepteurs aux angiotensines, Losartan.
- physiopathologie : Défaillance cardiaque, Rein.
- traitement médicamenteux : Défaillance cardiaque.
- Facteurs temps, Humains, Rein, Relation dose-effet des médicaments, Résultat thérapeutique, Taux de filtration glomérulaire, Études de suivi, Études rétrospectives.
English descriptors
- KwdEn :
- Angiotensin Receptor Antagonists (administration & dosage), Dose-Response Relationship, Drug, Follow-Up Studies, Glomerular Filtration Rate (drug effects), Heart Failure (drug therapy), Heart Failure (physiopathology), Humans, Kidney (drug effects), Kidney (physiopathology), Losartan (administration & dosage), Retrospective Studies, Time Factors, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Angiotensin Receptor Antagonists, Losartan.
- drug effects : Glomerular Filtration Rate, Kidney.
- drug therapy : Heart Failure.
- physiopathology : Heart Failure, Kidney.
- Dose-Response Relationship, Drug, Follow-Up Studies, Humans, Retrospective Studies, Time Factors, Treatment Outcome.
Abstract
This study investigated the dose-related effect of losartan on changes in renal function using data from the HEAAL (Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan) trial.
DOI: 10.1016/j.jchf.2014.11.004
PubMed: 25742759
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25742759Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.</title><author><name sortKey="Kiernan, Michael S" sort="Kiernan, Michael S" uniqKey="Kiernan M" first="Michael S" last="Kiernan">Michael S. Kiernan</name><affiliation wicri:level="2"><nlm:affiliation>Division of Cardiology, Tufts Medical Center, Boston, Massachusetts. Electronic address: mkiernan@tuftsmedicalcenter.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Division of Cardiology, Tufts Medical Center, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Gregory, Douglas" sort="Gregory, Douglas" uniqKey="Gregory D" first="Douglas" last="Gregory">Douglas Gregory</name><affiliation wicri:level="2"><nlm:affiliation>Cardiovascular Clinical Science Foundation, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Cardiovascular Clinical Science Foundation, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Sarnak, Mark J" sort="Sarnak, Mark J" uniqKey="Sarnak M" first="Mark J" last="Sarnak">Mark J. Sarnak</name><affiliation wicri:level="2"><nlm:affiliation>Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Division of Nephrology, Tufts Medical Center, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><affiliation wicri:level="3"><nlm:affiliation>Inserm 1433 Clinical Investigation Centre, Nancy University Hospital & University of Lorraine, Nancy and INI-CRCT F-CRIN, Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm 1433 Clinical Investigation Centre, Nancy University Hospital & University of Lorraine, Nancy and INI-CRCT F-CRIN, Nancy</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Nancy</settlement></placeName></affiliation></author><author><name sortKey="Massaro, Joseph" sort="Massaro, Joseph" uniqKey="Massaro J" first="Joseph" last="Massaro">Joseph Massaro</name><affiliation wicri:level="2"><nlm:affiliation>Boston University School of Public Health, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston University School of Public Health, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Kociol, Robb" sort="Kociol, Robb" uniqKey="Kociol R" first="Robb" last="Kociol">Robb Kociol</name><affiliation wicri:level="2"><nlm:affiliation>Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Division of Cardiology, Beth Israel Deaconess Medical Center, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation wicri:level="3"><nlm:affiliation>Inserm 1433 Clinical Investigation Centre, Nancy University Hospital & University of Lorraine, Nancy and INI-CRCT F-CRIN, Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm 1433 Clinical Investigation Centre, Nancy University Hospital & University of Lorraine, Nancy and INI-CRCT F-CRIN, Nancy</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Nancy</settlement></placeName></affiliation></author><author><name sortKey="Konstam, Marvin A" sort="Konstam, Marvin A" uniqKey="Konstam M" first="Marvin A" last="Konstam">Marvin A. Konstam</name><affiliation wicri:level="2"><nlm:affiliation>Division of Cardiology, Tufts Medical Center, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Division of Cardiology, Tufts Medical Center, Boston</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="doi">10.1016/j.jchf.2014.11.004</idno><idno type="RBID">pubmed:25742759</idno><idno type="pmid">25742759</idno><idno type="wicri:Area/PubMed/Corpus">000059</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000059</idno><idno type="wicri:Area/PubMed/Curation">000059</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000059</idno><idno type="wicri:Area/PubMed/Checkpoint">000056</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000056</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.</title><author><name sortKey="Kiernan, Michael S" sort="Kiernan, Michael S" uniqKey="Kiernan M" first="Michael S" last="Kiernan">Michael S. Kiernan</name><affiliation wicri:level="2"><nlm:affiliation>Division of Cardiology, Tufts Medical Center, Boston, Massachusetts. Electronic address: mkiernan@tuftsmedicalcenter.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Division of Cardiology, Tufts Medical Center, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Gregory, Douglas" sort="Gregory, Douglas" uniqKey="Gregory D" first="Douglas" last="Gregory">Douglas Gregory</name><affiliation wicri:level="2"><nlm:affiliation>Cardiovascular Clinical Science Foundation, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Cardiovascular Clinical Science Foundation, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Sarnak, Mark J" sort="Sarnak, Mark J" uniqKey="Sarnak M" first="Mark J" last="Sarnak">Mark J. Sarnak</name><affiliation wicri:level="2"><nlm:affiliation>Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Division of Nephrology, Tufts Medical Center, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><affiliation wicri:level="3"><nlm:affiliation>Inserm 1433 Clinical Investigation Centre, Nancy University Hospital & University of Lorraine, Nancy and INI-CRCT F-CRIN, Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm 1433 Clinical Investigation Centre, Nancy University Hospital & University of Lorraine, Nancy and INI-CRCT F-CRIN, Nancy</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Nancy</settlement></placeName></affiliation></author><author><name sortKey="Massaro, Joseph" sort="Massaro, Joseph" uniqKey="Massaro J" first="Joseph" last="Massaro">Joseph Massaro</name><affiliation wicri:level="2"><nlm:affiliation>Boston University School of Public Health, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston University School of Public Health, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Kociol, Robb" sort="Kociol, Robb" uniqKey="Kociol R" first="Robb" last="Kociol">Robb Kociol</name><affiliation wicri:level="2"><nlm:affiliation>Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Division of Cardiology, Beth Israel Deaconess Medical Center, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation wicri:level="3"><nlm:affiliation>Inserm 1433 Clinical Investigation Centre, Nancy University Hospital & University of Lorraine, Nancy and INI-CRCT F-CRIN, Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm 1433 Clinical Investigation Centre, Nancy University Hospital & University of Lorraine, Nancy and INI-CRCT F-CRIN, Nancy</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Nancy</settlement></placeName></affiliation></author><author><name sortKey="Konstam, Marvin A" sort="Konstam, Marvin A" uniqKey="Konstam M" first="Marvin A" last="Konstam">Marvin A. Konstam</name><affiliation wicri:level="2"><nlm:affiliation>Division of Cardiology, Tufts Medical Center, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Division of Cardiology, Tufts Medical Center, Boston</wicri:cityArea></affiliation></author></analytic><series><title level="j">JACC. Heart failure</title><idno type="eISSN">2213-1787</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin Receptor Antagonists (administration & dosage)</term><term>Dose-Response Relationship, Drug</term><term>Follow-Up Studies</term><term>Glomerular Filtration Rate (drug effects)</term><term>Heart Failure (drug therapy)</term><term>Heart Failure (physiopathology)</term><term>Humans</term><term>Kidney (drug effects)</term><term>Kidney (physiopathology)</term><term>Losartan (administration & dosage)</term><term>Retrospective Studies</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines (administration et posologie)</term><term>Défaillance cardiaque (physiopathologie)</term><term>Défaillance cardiaque (traitement médicamenteux)</term><term>Facteurs temps</term><term>Humains</term><term>Losartan (administration et posologie)</term><term>Rein ()</term><term>Rein (physiopathologie)</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term><term>Taux de filtration glomérulaire ()</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Losartan</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines</term><term>Losartan</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Glomerular Filtration Rate</term><term>Kidney</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Heart Failure</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Défaillance cardiaque</term><term>Rein</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Heart Failure</term><term>Kidney</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Défaillance cardiaque</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Follow-Up Studies</term><term>Humans</term><term>Retrospective Studies</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs temps</term><term>Humains</term><term>Rein</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term><term>Taux de filtration glomérulaire</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study investigated the dose-related effect of losartan on changes in renal function using data from the HEAAL (Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan) trial.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25742759</PMID><DateCreated><Year>2015</Year><Month>03</Month><Day>06</Day></DateCreated><DateCompleted><Year>2015</Year><Month>12</Month><Day>03</Day></DateCompleted><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2213-1787</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JACC. Heart failure</Title><ISOAbbreviation>JACC Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.</ArticleTitle><Pagination><MedlinePgn>214-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jchf.2014.11.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-1779(14)00535-6</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study investigated the dose-related effect of losartan on changes in renal function using data from the HEAAL (Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan) trial.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Angiotensin receptor blockers adversely affect renal function in patients with heart failure (HF). The time course and dose dependency of this time course, as well as the clinical implications of these changes in renal function, are not well described.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Subjects in the HEAAL dataset (n = 3,843) were studied. Changes in estimated glomerular filtration rate (eGFR) over time were compared between dose groups. The association between the timing of incident increases in serum creatinine (SCr) >0.3 mg/dl and clinical outcomes was explored.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with 50 mg, 150 mg losartan led to a greater reduction in eGFR across time (mean difference:-3.76 ml/min/1.73 m(2); p < 0.0001). This difference was driven by early changes, and differences in eGFRafter 4 months were not significant (mean difference: 0.42 ml/min/1.73 m(2); p = 0.15) [corrected]. Although an increase in SCr >0.3 mg/dl from baseline was associated with increased risk of death or hospitalization for HF (hazard ratio [HR]: 1.36; p < 0.0001), the relationship was not significant if the change occurred before 4 months (HR: 1.09; p = 0.20). Despite increased risk of worsening renal function, 150 mg losartan was associated with reduced risk of death or hospitalization for HF compared with 50 mg (HR: 0.85; p < 0.0001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Compared with 50 mg, 150 mg losartan is associated with an increased risk of acute rise in SCr, as well as with greater long-term reductions in eGFR. Despite these effects, high-dose losartan retains its net clinical benefit and is associated with reduced risk of death or hospitalization for HF. (Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure; NCT00090259).</AbstractText><CopyrightInformation>Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Tufts Medical Center, Boston, Massachusetts. Electronic address: mkiernan@tuftsmedicalcenter.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiovascular Clinical Science Foundation, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarnak</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossignol</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Inserm 1433 Clinical Investigation Centre, Nancy University Hospital & University of Lorraine, Nancy and INI-CRCT F-CRIN, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massaro</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kociol</LastName><ForeName>Robb</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zannad</LastName><ForeName>Faiez</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Inserm 1433 Clinical Investigation Centre, Nancy University Hospital & University of Lorraine, Nancy and INI-CRCT F-CRIN, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konstam</LastName><ForeName>Marvin A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Tufts Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00090259</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Heart Fail</MedlineTA><NlmUniqueID>101598241</NlmUniqueID><ISSNLinking>2213-1779</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>JMS50MPO89</RegistryNumber><NameOfSubstance UI="D019808">Losartan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JACC Heart Fail. 2015 Jun;3(6):510-1</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D057911">Angiotensin Receptor Antagonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005919">Glomerular Filtration Rate</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006333">Heart Failure</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019808">Losartan</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">angiotensin receptor blocker</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">renal failure</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S2213-1779(14)00535-6</ArticleId><ArticleId IdType="doi">10.1016/j.jchf.2014.11.004</ArticleId><ArticleId IdType="pubmed">25742759</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li><li>États-Unis</li></country><region><li>Grand Est</li><li>Lorraine (région)</li><li>Massachusetts</li></region><settlement><li>Nancy</li></settlement></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Kiernan, Michael S" sort="Kiernan, Michael S" uniqKey="Kiernan M" first="Michael S" last="Kiernan">Michael S. Kiernan</name></region><name sortKey="Gregory, Douglas" sort="Gregory, Douglas" uniqKey="Gregory D" first="Douglas" last="Gregory">Douglas Gregory</name><name sortKey="Kociol, Robb" sort="Kociol, Robb" uniqKey="Kociol R" first="Robb" last="Kociol">Robb Kociol</name><name sortKey="Konstam, Marvin A" sort="Konstam, Marvin A" uniqKey="Konstam M" first="Marvin A" last="Konstam">Marvin A. Konstam</name><name sortKey="Massaro, Joseph" sort="Massaro, Joseph" uniqKey="Massaro J" first="Joseph" last="Massaro">Joseph Massaro</name><name sortKey="Sarnak, Mark J" sort="Sarnak, Mark J" uniqKey="Sarnak M" first="Mark J" last="Sarnak">Mark J. Sarnak</name></country><country name="France"><region name="Grand Est"><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name></region><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000056 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000056 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25742759
|texte= Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25742759" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a InforLorV4
| This area was generated with Dilib version V0.6.33. |  |